Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD3 long-term extension study of ESK-001 in plaque psoriasis
jRCT2061250042Active, not recruiting
- Sponsor
- Alumis Inc.
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of envudeucitinib in plaque psoriasis, sponsored by Alumis Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious adverse events. Started Sep 2025; status: active, not recruiting.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2061250042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250042.